Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
Date:10/11/2007

n/infections.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,500 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

About Bayer Schering Pharma

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at http://www.bayerhealthcare.com.

<
'/>"/>
SOURCE Genzyme
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Genzyme Announces First Phase III Study of Tolevamer in Diarrhea Patients
2. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
3. Bayer Wins Positive Response For Marketing Its Cancer Drug
4. Genomatix Licensed By Bayer Healthcare
5. Bayer to Market Biocon Insulin in China
6. Test for Esophageal Reflux Licensed to Bayer by University
7. Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
8. Dow Acquires Wolff Walsrode from Bayer
9. Asmanex Twisthaler launched by Schering-Plough for treatment of asthma
10. India to benefit from pharma companies move
11. South Africa Wins landmark case against pharmaceutical giants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Recently, iFitDress.com, a famous online supplier of ... its range of 2014 seashell wedding dresses . ... prices. A large proportion of them are priced under ... are carefully made by the most skilled workers. Along ... gowns, ivory satin wedding gowns, white halter wedding gowns, ...
(Date:9/2/2014)... 02, 2014 TCG, a leading government technology ... as one of the fastest-growing companies in America for the ... TCG was previously recognized in 2013, 2012, 2011, 2010, 2009, ... has grown 86% from 2010 to 2013, ranking the company ... businesses in America - up 635 spots from 2013! More ...
(Date:9/2/2014)... Angeles, CA (PRWEB) September 02, 2014 ... article on its website titled “Why You Should Wash ... than 80 percent of the global population breathes air ... and particles of pollution lodge in the skin’s pores ... body’s natural barrier to free radicals that may cause ...
(Date:9/2/2014)... cancer cells can lay the groundwork for their own ... vessels to send out tumor-welcoming signals, according to a ... the Sept. 2 issue of Nature Communications , ... increased levels of so-called signaling molecules released by breast ... in the lungs and lymph nodes to produce proteins ...
(Date:9/2/2014)... Kathleen Doheny HealthDay Reporter ... U.S. obesity epidemic is a driving force behind the rising ... Researchers looked at data from five national surveys spanning ... in diabetes over time could be explained by factors such ... adults. The investigators found that the prevalence of diabetes ...
Breaking Medicine News(10 mins):Health News:Discounted Seashell Wedding Dresses Currently Provided By iFitDress.com 2Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3
... (Nasdaq: MEMY ) today announced the issuance ... matter patent,protection for a series of nicotinic alpha-7 ... which are both being developed,in partnership with Roche ... disease and cognitive impairment associated with schizophrenia,(CIAS). The ...
... Baby boomers are turning 62,every seven seconds. ... their,own health care in their senior years, says ... Care insurance lawyer., (Photo: http://www.newscom.com/cgi-bin/prnh/20070717/NYFNSC02 ), ... Care. It has been sold and,marketed to our ...
... ConvergeWireless Inc., of Ontario Canada, a Value Added Wireless Application ... been certified by the AT&T Developer Program. MyMileageGenie & MyFormsGenie ... for Enterprise Sales. , ... Ontario, ...
... DETROIT, Oct. 24 For the second ... has been chosen as the most,preferred hospital ... to the,2008 Cancer Treatment Preference Profile Survey ... http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELOGO ), The annual survey, ...
... body, checking arteries lowers risk of further injury , , THURSDAY, ... is only the first step in saving a life after ... advisory, published in the Oct. 23 issue of Circulation ... resuscitation or risk the losing the patient to the original ...
... Alternext US: FIT), a leading provider of integrated,employee ... report financial results for the third quarter ended ... the market closes. The company will also,hold a ... results. Participating,in the call will be Dr. Gregg ...
Cached Medicine News:Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 2Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 3Health News:Expert Says Conseco Trust May Significantly Alter The Senior Health Care Market 2Health News:MyMileageGenie & MyFormsGenie Certified by the AT&T Developer Program 2Health News:MyMileageGenie & MyFormsGenie Certified by the AT&T Developer Program 3Health News:MyMileageGenie & MyFormsGenie Certified by the AT&T Developer Program 4Health News:Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan 2Health News:Speedy Care After Heart Attack Key to Survival 2Health News:HealthFitness Corporation to Report 2008 Third Quarter Financial Results 2
(Date:9/2/2014)... 2014  Ameritox SM , the nation,s leader in ... Drugs to Heroin," a research report that provides concrete ... examines deadly trends that have created a unique heroin ... The report is based on data ... It examines five trends that distinguish the heroin abuse ...
(Date:9/2/2014)... BARCELONA , Spanien, September 2, ... -- Das auf dem ESC-Kongress 2014 ... die Behandlung und Behandlungsergebnisse von schlaganfallgefährdeten ...    Die Daten ... eingetragenen Patienten, einer innovativen und unabhängigen ...
(Date:9/2/2014)... Spain , September 2, 2014 ... decisions, including patients, quality of life and treatment satisfaction ... 2 ]   ... ESC Congress 2014, 02 September 2014, Barcelona, ... results of the PREvention oF thromboembolic events-European Registry in ...
Breaking Medicine Technology:Ameritox Research Report Reveals Pain Patients' Role in Current Heroin Epidemic 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8
... (Nasdaq: IDIX ), a biopharmaceutical company engaged ... treatment of human viral diseases, today reported unaudited financial ... September 30, 2010. At September 30, 2010, Idenix,s cash ... Third Quarter 2010 Financial ResultsFor the third quarter ended ...
... ViroPharma Incorporated (Nasdaq: VPHM ) today ... ViroPharma, will present at the Oppenheimer 21st Annual Healthcare ... 2010.  The conference is being held at the Waldorf=Astoria ... president and chief financial officer, of ViroPharma, will present ...
Cached Medicine Technology:Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results 2Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results 3Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results 4Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results 5ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences 2
... Basic ergonomic chairs with ... with lumbar support • Select ... and casters and glides. • ... the following environments: industry, education, ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTT/1P chairs are recommended for ... clean room, static control, health care ...
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: